Glaukos Corp. has submitted a PMA application seeking approval of its glaucoma Istent Inject trabecular micro-bypass stent. The firm's FDA submission has followed a prospective randomized trial indicating 20 percent reduction of intraocular pressure (IOP) at two years. Read More
